Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

In a nutshell Scientists discovered that an enzyme called SSAT1 turns helpful immune cells into harmful ones in psoriasis, ...

Posters presented at the 2025 American Academy of Dermatology Annual Meeting found bimekizumab to have benefits beyond safety ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

Researchers studied the relationship between 3 dermatological immune-mediated inflammatory diseases and COVID-19.

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

A systematic review revealed that patients with psoriasis have a significantly higher prevalence of onychomycosis than those without psoriasis.

Some evidence suggests a higher risk of liver disease with psoriasis. Certain psoriasis treatments can cause liver toxicity, but the two conditions also share common risk factors, which may ...

Dry skin, itching, and fiery eczema can be caused by allergens, stress, or an overactive immune response.Steroid creams ...